Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

Completed · Phase 3 · Has a placebo group

Conditions studied: Dry Eye

In brief

The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.

Key facts

Study ID

NCT01129856

Run by

Eyegate Pharmaceuticals, Inc.

People needed

198

Starts

2010-06-01

Expected to finish

2011-04-01

Last updated by the study team

2011-04-27

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a reported history of dry eye in each eye
• Be at least 12 years of age
• Demonstrate a response when exposed to the Controlled Adverse Environment model at Visits 1 and 2

You may not qualify if…

• Have contraindications to the use of the test articles
• Have known allergy or sensitivity to the study medications or their components
• Have any ocular infections, active ocular inflammation, or preauricular lymphadenopathy
• Be current contact lens wearers or wear contacts during the study

Where it is running

• The Eye Care Group — Waterbury, Connecticut, United States
• Central Maine Eye Care — Lewiston, Maine, United States
• Andover Eye Associates — Andover, Massachusetts, United States
• Total Eye Care — Memphis, Tennessee, United States
• Virginia Eye Consultants — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.